



3rd edition of the HealthTech Innovation Days - 4 & 5 October in Paris

Placed for the third consecutive year under the High Patronage of Mr Emmanuel Macron, President of the French Republic, the [HealthTech Innovation Days](#) (HTID®) will take place in the presence of several institutional representatives: M. Thierry Breton, European Commissioner for the Internal Market, Mrs Alexandra Dublanche, Vice-President of the Île-de-France Regional Council, Mrs Agnès Pannier-Runacher, Minister for Industry, M. Christian Pierret, former Minister for Industry, M. Laurent Saint-Martin, General Rapporteur of the National Assembly's Finance Committee, M. Alain Godard, CEO of the European Investment Fund and M. Jan-Philipp Beck, CEO of EIT Health.

HealthTech For Care and EIT Health detail the programme and confirm the mobilization around this event

Paris, France, September 17, 2021 - HTID® will bring together more than 500 inperson participants, including [international investors](#) including Abingworth Management Limited, Baillie Gifford, Bain Capital Public Equity, LP, Emerson Collective, Exor, Forbion, General Atlantic, Invus, KKR, Kreos, Medixi Ventures, New Enterprise Associates (NEA), Novo Holdings, PSP Investments, Redmile, Sectoral Asset Management, Sofinnova and Temasek along with more than [150 European companies](#) from more than 20 countries, as well as remote participants. The renewed confidence of its sponsors and the commitment of new partners attest the growing mobilisation of the health ecosystem in Europe.

One year following [the opening speech of Mr Emmanuel Macron, President of the French Republic](#), at the [HealthTech Innovation Days 2020](#), the 2021 edition will detail the economic and financial solutions put in place to face the consequences of the Covid-19 pandemic. In this context, experts will present the concrete means developed to increase the value of European health companies for investors and industrial partners.

Several speakers will share their views during the scheduled round-tables, including:

- **"Empower innovation in Healthtech to foster post pandemic EU's economic growth"**
Session moderated by Christian Pierret, Former French Minister of Industry who will review the role of innovation as an economic lever for the post-crisis period. This round table will take place on **Monday 4 October from 1 pm to 1:55 pm**: <https://htfc-eu.com/agenda-htid/>
- **"Industrial redevelopment in Europe, where to start?"** The speakers of the Round Table with Marc Dechamps, (CEBR Board President & Moderator of the session) will discuss the possibilities to relocate our health industry in Europe. On this occasion the CEBR (Council of European BioRegions) and EIT Health will present the findings of an innovative pan-European study on biomanufacturing issues. This round table will take place on **Monday 4 October from 2:00 pm to 2:55 pm**: <https://htfc-eu.com/agenda-htid/>

- **"How are disruptive technologies transforming the oncology landscape to fulfill patients' unmet needs?"** This panel, presented by Philippe Therasse, Vice-President late stage and life cycle management oncology, Servier (Moderator), will address the cross-cutting needs of cancer patients. This panel will take place on **Tuesday 5 October from 2:00 pm to 3:00 pm** : <https://htfc-eu.com/agenda-htid/>
- **"Infectious disease: emerging challenges in the pandemic era"**. The roundtable discussion moderated by Florence Séjourné, CEO, DA VOLTERRA & President at BEAM Alliance (Moderator), will reveal how the health crisis has cast a new light on infectious diseases. This round table will take place on Tuesday 5 October from 11:30 am to 12:30 pm: <https://htfc-eu.com/agenda-htid/>

In addition, the CEO of the European Investment Fund, Alain Godard, and the EIT Health France and Services & Investments Managing Director, Jean-Marc Bourez, will unveil the names of the selected corporate and venture capital funds of [the Venture Centre of Excellence](#), a co-investment programme cooperated with EIT Health which has benefited from a EUR150 million anchor investment from the European Commission. The latter was [announced at HTID in October 2020 by Mr. Thierry Breton, European Commissioner for the Internal Market. Consequently, the VCoE programme currently holds a](#) total investment capacity of EUR1.7 billion.

Other highlights will bring together international experts on central themes such as the use of AI, advances in robotics, the importance of human capital, the key involvement of patients and associations in the development of new care and finally the added value in the mastery of clinical data processing.

HTID[®], which promotes a new culture of innovation based on collaboration, is pleased to count among its patrons major global pharmaceutical groups such as [Amgen](#), [Bristol Myers Squibb](#), [Microsoft](#), [Sanofi](#), [Servier](#), influential players in healthtech, such as [Alpha Bue Ocean](#), [BNP Paribas](#), [Dechert](#), [Financière Arbevel](#), [Icosa](#), [Invest Securities](#), [McDermott Will & Emery](#), [Microsoft](#), [Rothschild&Co](#), [Sofinnova Partners](#), [Thermo Fisher Scientific](#) as well as institutional partners such as [Bpifrance](#), [Euronext](#) and [Leem](#).

This year HTID[®] will privilege a face-to-face format while maintaining virtual sessions, allowing for more than 80 international experts to speak about the economic, health and technological challenges facing the healthcare industry in order to accelerate patient access to innovative treatments in Europe.

About HealthTech For Care

The HealthTech For Care Endowment Fund is designed to support and promote access to care for all and, in particular, new medical technologies and drugs. The missions of the endowment fund are organized around three main areas: supporting the development of the entire healthcare ecosystem, accelerating the development of innovative therapies and medicines, and promoting better access for patients to the healthcare system in France and Europe. HealthTech For Care is supported by its founder **France Biotech** and the network of French health cluster: **Atlantpole biotherapies**, **France BioValley**, **EuroBioMed**, **LyonBioPole**, **Medicen et le clubster NSL**. The endowment fund is also supported by many European players: **Asebio**, **Bio Deutschland**, **BioWin**, **CEBR**, **Federchimica Assobiotec**, **Flanders.bio**, **Irefi**, **LifeSci**, **P-Bio**, **SwendenBio** and **SwissBiotech**.

About EIT Health

Europe faces a turning point in health. An ageing population, the rising burden of chronic disease, and growing multi-morbidity are all placing pressure on health systems across Europe.

EIT Health is a vast, vibrant community of world leading health innovators backed by the European Union. Working across borders, our network connects approximately 150 world-class partner organisations, as well as entrepreneurs, start-ups and SMEs from the worlds of business, research, education and healthcare delivery. Our aim is to answer the biggest health challenges Europe faces and we believe that life changing innovation happens when these worlds meet and collaborate. That's why we call this the 'knowledge triangle'.

From our headquarters in Munich, six regional Innovation Hubs and InnoStars cluster, which brings together organisations from regions in which the overall pace of innovation is more moderate, we provide an ecosystem in which fresh thinking can thrive. Our Regional Innovation Scheme further expands our presence in 13 countries across Central, Eastern and Southern Europe. EIT Health also leads the development of the EIT Hub in Israel, which connects innovators across Europe to other key thriving ecosystems beyond the EU. EIT Health is supported by the European Institute of Innovation and Technology (EIT), a body of the European Union. Our ambition is to enable people in Europe to live longer, healthier lives by transforming businesses and delivering new products and services that can progress healthcare in Europe and strengthen our economy.

EIT Health: Together for healthy lives in Europe.

For more information visit: www.eithealth.eu

About LifeSci Advisors

LifeSci Advisors are the global leading investor relations firm within Life Sciences. We combine deep domain life sciences expertise with decades of experience in capital markets to deliver services designed to increase our clients' visibility within the investment community. For more information visit: <https://www.lifesciadvisors.com>

About France Biotech, Founder of HealthTech For Care

Founded in 1997, France Biotech is an independent association that brings together HealthTech entrepreneurs and their expert partners. It actively contributes to meet the many challenges of the HealthTech industry (i.e. companies' financing, innovation-related taxes, regulatory and market access related issues) and offers concrete competition and solutions through its commissions and working groups. The goal is to help startups and SMEs become international leaders capable of rapidly developing and bringing innovative solutions to patients. <http://www.france-biotech.fr/>

About HealthTech Innovation Days

The HTID[®] event provides a platform for promising European life sciences companies to accelerate their growth and bring innovation to patients. The conference will take place on October 4&5 2021 on a hybrid format, combining in-person presentations, panels and one-on-one meetings in Paris with a seamless virtual platform for those unable to travel. It is organized by HealthTech For Care and EIT Health, a network of best-in-class health innovators backed by the EU, to enable partnerships between healthcare companies as well as to secure funding from international, specialized healthcare investors. The HealthTech Innovation Days are sponsored by international pharmaceutical companies, other corporates, investors, and many international thought leaders. <https://htfc-eu.com/htid/>

Press contacts

Press relations

Najette Chaib

najettechaib@outlook.com

+33(0)6 18 38 11 14

EIT Health

Jérôme Fabiano

jerome.fabiano@eithealth.eu

+33(0) 6 42 25 73 41

LifeSci Advisors

Sophie Baumont

sophie@lifesciadvisors.com

+33(0) 6 27 74 74 49

HTFC

Nathalie Donne

nathalie.donne@insead.eu

+33(0)6 67 67 44 97

HTFC

Solène Goupy

solene.goupy@htfc-eu.com

+33(0)6 38 03 80 19

France Biotech

Florence Portejoie

FP2COM

fportejoie@fp2com.fr

+33(0)6 07 76 82 83